Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 143

Sort by

Sort Order Select

Journal Articles

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Blood blood.2024025690.

https://doi.org/10.1182/blood.2024025690

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Craig C. Hofmeister, Vikas A. Gupta, Jonathan L. Kaufman, Ajay K. Nooka, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar

Blood (2024) 144 (Supplement 1): 255.

https://doi.org/10.1182/blood-2024-202102

Published: 2024

Journal Articles

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Cindy Varga, Myra Robinson, Vikas Gupta, Craig C. Hofmeister, Ajay K. Nooka, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Shanice Borden, Christopher Ferreri, Barry Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 4702.

https://doi.org/10.1182/blood-2024-204388

Published: 2024

Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau

Blood (2024) 144 (Supplement 1): 4757.1.

https://doi.org/10.1182/blood-2024-199752

Published: 2024

Journal Articles

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Blood (2024) 144 (Supplement 1): 861.

https://doi.org/10.1182/blood-2024-200277

Published: 2024

Journal Articles

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Shree Allada, Vikas A. Gupta, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Nisha S. Joseph

Blood (2024) 144 (Supplement 1): 7861.

https://doi.org/10.1182/blood-2024-210996

Published: 2024

Journal Articles

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Nisha S. Joseph, Shruti Gupta, Jonathan L. Kaufman, Sara Dicamillo, Danielle Roberts, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka

Blood (2024) 144 (Supplement 1): 7870.

https://doi.org/10.1182/blood-2024-211988

Published: 2024

Journal Articles

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Paula Rodríguez-Otero, Joshua Richter, Ajay K. Nooka, Fredrik Schjesvold, Emily Combe, Leanne Cooper, Ollie Schofield, Indeg Sly, Nick Ballew, Jacopo Bitetti, Natalie Boytsov, Simon McNamara, Molly Purser

Blood (2024) 144 (Supplement 1): 7054.

https://doi.org/10.1182/blood-2024-198712

Published: 2024

Journal Articles

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Lilly Gu, Nisha S. Joseph, Vikas A. Gupta, Craig C. Hofmeister, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3780.

https://doi.org/10.1182/blood-2024-211474

Published: 2024

Journal Articles

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Lorenzo Cani, Sara A. Scott, Nisha S. Joseph, Craig C. Hofmeister, Vikas A. Gupta, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 3311.

https://doi.org/10.1182/blood-2024-206155

Published: 2024

Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Blood (2024) 144 (Supplement 1): 4653.

https://doi.org/10.1182/blood-2024-200333

Published: 2024

Journal Articles

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

Gabriel Najarro, Vikas A. Gupta, Nisha S. Joseph, Jonathan L. Kaufman, Ajay K. Nooka, Madhav V. Dhodapkar, Sagar Lonial, Craig C. Hofmeister

Blood (2024) 144 (Supplement 1): 5142.

https://doi.org/10.1182/blood-2024-202078

Published: 2024

Journal Articles

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Craig C. Hofmeister, Vikas A. Gupta, Nisha S. Joseph, Sagar Lonial, Madhav V. Dhodapkar, Ajay K. Nooka, Jonathan L. Kaufman

Blood (2024) 144 (Supplement 1): 4672.

https://doi.org/10.1182/blood-2024-203485

Published: 2024

Journal Articles

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Shannon M Matulis, Robert M Chavez, Rebecca Owens, Arun P Wiita, Mala Shanmugam, Ricardo De Matos Simoes, Constantine S Mitsiades, Nisha S. Joseph, Craig C. Hofmeister, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Vikas A. Gupta, Jonathan D. Licht, Benjamin G. Barwick, Lawrence H. Boise

Blood (2024) 144 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2024-210441

Published: 2024

Journal Articles

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Blood (2024) 144 (Supplement 1): 3331.

https://doi.org/10.1182/blood-2024-200354

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Joseph C. Cappelleri, Umberto Conte

Blood (2024) 144 (Supplement 1): 1933.

https://doi.org/10.1182/blood-2024-203723

Published: 2024

Journal Articles

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Noa Biran, Binod Dhakal, Ruben Niesvizky, Suzanne Lentzsch, John T Mckay, David H. Vesole, Ajay K. Nooka, Barry Paul, Parameswaran N. Hari, Silvia D'Ambrosi, Rowan Kuiper, Martin H van Vliet, David S. Siegel, Saad Z. Usmani, Frits van Rhee

Blood (2024) 144 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2024-209903

Published: 2024

NARROW

Heme promotes venetoclax resistance in multiple myeloma through MEK-ERK signaling and purine biosynthesis

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

A Randomized Trial Demonstrates a 3-Shot Flu Vaccine Series Improves Protection over a Single Shot in Multiple Myeloma

Stem Cell Mobilization Yields with Daratumumab (Dara) and Lenalidomide (Len)-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Real-World Experience at Two Institutes

Iopofosine I 131 in Previously Treated Patients with Waldenström Macroglobulinemia (WM): Efficacy and Safety Results from the International, Multicenter, Open-Label Phase 2 Study (CLOVER-WaM™)

Single Center Institutional Experience and Outcomes Administering Both Anti-BCMA and Anti-GPRC5D Bispecific T-Cell Engagers

Impact of Self-Identified Race on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients Receiving Induction Therapy with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Belantamab Mafodotin + Bortezomib + Dexamethasone Versus 2L+ Relapsed/Refractory Multiple Myeloma Regimens: Lenalidomide-Exposed, Lenalidomide-Refractory, High-Risk Cytogenic, and 2L-Only Subpopulations: A Network Meta-Analysis

Characterization of Newly Diagnosed Multiple Myeloma (NDMM) Patients with Early Progression Following Induction with Daratumumab, Lenalidomide, Bortezomib and Dexamethasone (D-RVd)

Risk of Infections in Multiple Myeloma Patients Treated with Bispecific Antibodies

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Serum Free Light Chain Ratio Is Inversely Proportional to the Egfr, and Has Been Increasing over the Last Decade

A Slow-Go Treatment in Newly Diagnosed AL Amyloidosis with Severe Cardiomyopathy

Mitochondrial Priming Is Heterogenous in t(4;14) Multiple Myeloma and Can be Induced By Inhibition of NSD2

Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

The Effect of Elranatamab on Patient-Reported Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Naïve and Exposed to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Updated Follow-Up from the MagnetisMM-3 Study

Enhanced Prognostic Value of the SKY92 Classifier over High-Risk Cytogenetic Aberrations in Multiple Myeloma: Results from the Prommis Real-World Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only